Selected Grants
Novartis: Single-Arm, Open-Label, Ph2 of MBG453 added to Hypomethylating Agent for MDS
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2022 - 2026CLNP023C12303
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2023 - 2026Apellis AP2-307--Extension PNH
Clinical TrialPrincipal Investigator · Awarded by Apellis Pharmaceuticals, Inc · 2020 - 2025EQAPOL OPTION 6 (YEAR 7)
ResearchMedical Director · Awarded by National Institutes of Health · 2017 - 2024EQAPOL - Years 2017 to 2024 - BASE
ResearchDirector · Awarded by National Institutes of Health · 2017 - 2024Novartis: Single-Arm, Open-Label, Ph2 of MBG453 added to Hypomethylating Agent for MDS
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2022 - 2026CLNP023C12303
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2023 - 2026Apellis AP2-307--Extension PNH
Clinical TrialPrincipal Investigator · Awarded by Apellis Pharmaceuticals, Inc · 2020 - 2025EQAPOL OPTION 6 (YEAR 7)
ResearchMedical Director · Awarded by National Institutes of Health · 2017 - 2024EQAPOL - Years 2017 to 2024 - BASE
ResearchDirector · Awarded by National Institutes of Health · 2017 - 2024A randomized, multicenter, active-comparator controlled, open-label trial to evaluate efficacy and safety of oral, twice daily LNP023 in adult patients with PNH and residual anemia, despite treatment with intravenous anti-C5 antibody
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2021 - 2024A Phase III, Randomized, Multi-Center, Open-Label, Active-Comparator Controlled Study To Evaluate the Efficacy and Safety of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Clinical TrialPrincipal Investigator · Awarded by Apellis Pharmaceuticals, Inc · 2019 - 2023A Phase 3 Study of Danicopan (ALXN2040) as Add-on Therapy to a C5 Inhibitor (Eculizumab or Ravulizumab) in Patients with Paroxysmal
Clinical TrialPrincipal Investigator · Awarded by Alexion Pharmaceuticals, Inc. · 2021 - 2023A Phase 3, Double-Blind, Placebo-controlled study of Quizartinib (AC220) Administered in Combination with Induction and Consolidation Chemotherapy, and Administered as Maintenance Therapy in Subjects 18 to 75 Years Old with Newly Diagnosed FLT3-ITD
Clinical TrialPrincipal Investigator · Awarded by Daiichi Sankyo Inc · 2016 - 2022A randomized, double-blind phase 3 study of vadastuximab talirine (SGN-CD33A) versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute myeloid leukemia (AML)
Clinical TrialPrincipal Investigator · Awarded by Seattle Genetics, Inc · 2016 - 2021Strategies to overcome immunotherapy resistance in LKB1 and KEAP/NRF2 mutated NSCLC: modulating ferroptosis to restore immune sensitivity
FellowshipSponsor · Awarded by Society for Immunotherapy of Cancer · 2020 - 2021Phase II study to evaluate safety of Azacitidine PLUS Durvalumab (medi4736) in MDS/AML
Clinical TrialPrincipal Investigator · Awarded by Celgene Corporation · 2016 - 2021An Open Label study to assess the safety of APL-2 as an Add-on to standard of care in subjects with PNH
Clinical TrialPrincipal Investigator · Awarded by Apellis Pharmaceuticals, Inc · 2014 - 2019A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination with Chemotherapy in Patients with Acute Myeloid Leukemia (AML)
Clinical TrialPrincipal Investigator · Awarded by Gilead Sciences, Inc. · 2017 - 2019Phase III study of AG-221(CC-90007) with late AML harboring Isocitrate Dehydrogenase 2 mutation
Clinical TrialPrincipal Investigator · Awarded by Celgene Corporation · 2016 - 2019RA101495-01.203: A Phase 2 Multicenter, Open-Label, Uncontrolled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmaqcokinetics, and Pharm
Clinical TrialPrincipal Investigator · Awarded by Ra Pharmaceuticals, Inc · 2017 - 2018RA101495-01.202: A multicenter, Open-Label, Uncontrolled, Extension Study of RA101495 in Subjects with Paroxysmal Nocturnal Hemoglobinuria Who Have Completed a RA101495 Clinical Study
Clinical TrialPrincipal Investigator · Awarded by Ra Pharmaceuticals, Inc · 2017 - 2018A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment
Clinical TrialPrincipal Investigator · Awarded by Janssen Research & Development, LLC · 2016 - 2018A Phase 2, Randomized, Controlled, Open-Label, Clinical Study of the Efficacy and Safety of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
Clinical TrialPrincipal Investigator · Awarded by Millennium Pharmaceuticals, Inc. · 2016 - 2018A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Complement Inhibitor-Naive Adult Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Clinical TrialPrincipal Investigator · Awarded by Alexion Pharmaceuticals, Inc. · 2017 - 2017EQAPOL Option 5
ResearchInvestigator · Awarded by National Institutes of Health · 2010 - 2017EQAPOL - 2016 to 2017 - Option 6 - BASE
ResearchDirector · Awarded by National Institutes of Health · 2010 - 2017Role Of C-Kit In Early Hematopoiesis
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1991 - 1996External Relationships
- Alexion Pharmaceuticals, Inc. a subsidiary of AstraZeneca
- Apellis Pharmaceuticals
- Genentech
- Novartis
- Omeros Pharmaceutical
- Alexion Pharmaceuticals, Inc. a subsidiary of AstraZeneca
- Apellis Pharmaceuticals
- Genentech
- Novartis
- Omeros Pharmaceutical
- Regeneron Pharmaceuticals
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.